Company Overview
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company that delivers advanced therapeutic solutions through its proprietary nPulse System and related percutaneous electrode technologies. The enterprise functions within the Healthcare sector, specifically categorized under the Medical Instruments & Supplies industry, which implies a focus on manufacturing and distributing specialized medical devices rather than pharmaceutical production. The company maintains a market capitalization of $1.48B while reporting an annual revenue of $350,000 and employing a workforce of 116 individuals. These valuation and revenue figures indicate that the company is currently a high-capitalization entity relative to its current revenue output, suggesting a significant reliance on future potential, asset value, or market speculation rather than current operational profitability to sustain its listed status. The disparity between the substantial market cap and the minimal revenue highlights the market's pricing of the company based on its technology platform and growth expectations rather than immediate cash generation.
Financial Health
Pulse Biosciences, Inc. reported revenue of $350,000 over the trailing twelve months, yet it recorded a net income of $-72,781,000 and an EBITDA of $-75,868,000. The substantial gap between the nominal revenue and the massive net loss reveals an extremely aggressive cost structure where operating expenses and research and development costs far exceed all sales proceeds. The company generated free cash flow of $-29,515,876, which indicates a severe lack of financial flexibility as the business is consuming its own liquidity to fund operations and growth initiatives. All three margin metrics reflect this structural deficit: the gross margin stands at -54.0%, the operating margin is -6914.0%, and the profit margin is 0.0%. These negative and disproportionately large margin figures indicate that for every dollar of revenue generated, the company incurs costs that result in significant losses before tax and interest considerations. On the balance sheet, the company holds $80.73M in cash against $7.53M in debt, resulting in a debt-to-equity ratio of 9.34. This leverage position suggests a highly leveraged balance sheet relative to equity, although the substantial cash reserve provides a buffer against immediate solvency concerns. The current ratio of 10.53 indicates strong short-term liquidity, as the company possesses ample current assets to cover its current liabilities many times over. Return on Equity is -74.4% and Return on Assets is -42.4%, metrics that reveal management is currently destroying shareholder and asset value rather than generating returns.
Valuation Assessment
The valuation metrics present a complex picture with a P/E Ratio (TTM) of N/A and a Forward P/E of -25.40. The difference between a nonexistent trailing P/E and a negative forward P/E implies that the market expects the company to eventually generate positive earnings, but current trajectories show losses that preclude standard earnings-based valuation models. The price-to-book ratio is 18.37, which indicates that the market is valuing the company at a significant premium of 18.37 times its net asset value, a figure that is often unsustainable for companies with negative earnings. Alternative valuation metrics such as the price-to-sales ratio of 4242.52 and the EV/EBITDA of -18.84 further suggest that traditional valuation multiples are inapplicable due to the lack of profitability and the negative enterprise value. The stock's price range over the past year spans from a 52-week low of $12.56 to a 52-week high of $26.30. Without a specific current price provided in the data, the relative positioning cannot be calculated, but the range demonstrates the stock's sensitivity to market sentiment regarding its biotech potential. The beta value of 1.82 indicates that the stock is highly volatile relative to the broader market, moving 1.82 times as much as the market index during periods of fluctuation.
Growth & Income
The company's revenue growth (YoY) is listed as N/A, and earnings growth (YoY) is also N/A, precluding a direct comparison of growth rates between earnings and revenue in the current reporting period. Since the net income is deeply negative, the concept of sustainable dividend growth does not apply in the traditional sense. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute earnings to shareholders, effectively reinvesting all available capital, including cash reserves, into its operations and research efforts. This reinvestment strategy is typical for early-stage medical device companies attempting to commercialize novel platforms like the nPulse System to achieve future profitability. The overall growth and income profile is characterized by a complete absence of current income generation and reported growth metrics, relying entirely on the conversion of cash reserves and market capital into future product launches and market penetration.